Barclays PLC raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 31.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 545,008 shares of the company's stock after acquiring an additional 131,743 shares during the period. Barclays PLC owned approximately 0.29% of BridgeBio Pharma worth $13,876,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. Bfsg LLC grew its position in BridgeBio Pharma by 175.6% in the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company's stock worth $31,000 after purchasing an additional 790 shares during the period. Headlands Technologies LLC bought a new position in shares of BridgeBio Pharma during the 2nd quarter valued at $48,000. Values First Advisors Inc. purchased a new position in shares of BridgeBio Pharma in the 3rd quarter worth $57,000. CWM LLC grew its holdings in shares of BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company's stock worth $88,000 after acquiring an additional 1,964 shares during the period. Finally, Advisors Asset Management Inc. increased its position in BridgeBio Pharma by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock valued at $117,000 after acquiring an additional 1,645 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.
BridgeBio Pharma stock opened at $27.49 on Monday. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $44.32. The company's 50-day moving average price is $25.58 and its 200-day moving average price is $26.10. The company has a market cap of $5.20 billion, a PE ratio of -11.41 and a beta of 1.08.
Several brokerages have issued reports on BBIO. Piper Sandler began coverage on BridgeBio Pharma in a research report on Wednesday, September 4th. They issued an "overweight" rating and a $46.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $70.00 price objective on shares of BridgeBio Pharma in a research note on Monday, September 16th. Leerink Partners reduced their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating for the company in a report on Thursday, October 17th. Oppenheimer began coverage on shares of BridgeBio Pharma in a report on Thursday, October 3rd. They set a "market perform" rating on the stock. Finally, HC Wainwright increased their price objective on shares of BridgeBio Pharma from $43.00 to $49.00 and gave the stock a "buy" rating in a research note on Monday, November 25th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, BridgeBio Pharma has an average rating of "Moderate Buy" and an average price target of $47.69.
Read Our Latest Analysis on BBIO
In other news, CEO Neil Kumar sold 27,389 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the sale, the chief executive officer now owns 4,897,443 shares of the company's stock, valued at approximately $109,751,697.63. This represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Brian C. Stephenson sold 4,156 shares of BridgeBio Pharma stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $93,135.96. Following the transaction, the chief financial officer now directly owns 93,758 shares of the company's stock, valued at approximately $2,101,116.78. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.66% of the stock is currently owned by insiders.
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.